Navidea Biopharmaceuticals, Inc. (NYSE:NAVB – Free Report) was the recipient of a large decline in short interest in June. As of June 15th, there was short interest totalling 570,200 shares, a decline of 35.3% from the May 31st total of 881,100 shares. Based on an average daily trading volume, of 5,430,000 shares, the short-interest ratio […]
Stock analysts at StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) in a report released on Sunday. The brokerage set a “sell” rating on the stock. Navidea Biopharmaceuticals Price Performance About Navidea Biopharmaceuticals (Get Rating) Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents […]
StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) in a report issued on Friday. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance Shares of NYSE:NAVB opened at $0.10 on Friday. Navidea Biopharmaceuticals has a 12-month low of $0.08 and a 12-month high of $1.05. The company […]
Analysts at StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) in a research report issued on Friday. The brokerage set a “sell” rating on the stock. Navidea Biopharmaceuticals Stock Up 14.5 % Shares of Navidea Biopharmaceuticals stock opened at $0.10 on Friday. Navidea Biopharmaceuticals has a 52 week low of $0.08 […]
StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) in a report published on Tuesday. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Up 5.3 % Shares of NYSE:NAVB opened at $0.26 on Tuesday. Navidea Biopharmaceuticals has a 12 month low of $0.16 and a 12 month high […]